| Literature DB >> 26282628 |
Anthony Alozie1, Annette Zimpfer2, Kerstin Köller3, Bernd Westphal4, Annette Obliers5, Andreas Erbersdobler6, Gustav Steinhoff7, Andreas Podbielski8.
Abstract
BACKGROUND: Whipple's disease is a rare, often multisystemic chronic infectious disease caused by the rod-shaped bacterium Tropheryma whipplei. Very rarely the heart is involved in the process of the disease, leading to culture-negative infective endocarditis. Up to 20 % of all infective endocarditis are blood culture-negative and therefore a diagnostic challenge. We present two unusual cases of culture-negative infective endocarditis encountered in two different patients with prior history of arthralgia. A history of rheumatic arthritis or even a transient arthralgia should put Tropheryma whipplei on the top of differentials in patients of this age group presenting with culture-negative infective endocarditis, especially in cases of therapy resistance to antirheumatic agents. CASEEntities:
Mesh:
Year: 2015 PMID: 26282628 PMCID: PMC4539700 DOI: 10.1186/s12879-015-1078-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1a–d: Whipple endocarditis and pericarditis in a 55-year old patient. a. TEE showing a severe degenerative aortic valve and aortic valve vegetations with aortic regurgitation III°. b. Severely degenerative and calcific aortic disease with chronic ulcerations (Pas, 2x, inset: hematoxillin&eosin, 2x). *labels the area visualized in 1C. c. Demonstration of Pas-reactive foamy macrophages, which contained T. whipplei particles. Note: the macrophages are seen in relation to capillaries (Pas, 100x, inset: Pas, 10x). d. Pericardium with extensive sclerosis and calcification (hematoxillin&eosin, 2x)
Fig. 2a–d: Whipple endocarditis in a 65- year- old patient. a/b. TEE displaying degenerative aortic valve with vegetations. b. Mild degenerative aortic valve changes with pronounced edema, fibrin insudation and superficial collections of foamy macrophages (haematoxillin&eosin, 4x). d. Demonstration of Pas-reactive foamy macrophages, which contained T. whipplei particles (Pas, 20x)
Reports indicating alteration of the course of subacute Whipple’s disease during therapy with biological agents
| Nr. | Reports Indicating Potential Fatal Complications Of Biological Therapy During Sero-negative Rheumatoid Arthritis. | |||||||
|---|---|---|---|---|---|---|---|---|
| Author | Journal | Yr of Pub | Nr. of Pat. | Initial symptoms/Duration | Therapy | Results | Conclusion/Finding | |
| [ | Mahnel R. et al. | Am. J. Gastroenterol. | 2005 | 27 | Immunosuppressiva lead to earlier onset of diarrhea | |||
| [ | Kneitz C. et al. | Scand. J. Rheumatol. | 2005 | 1 | Infliximab/MTX | Rapid weight loss Erythema nodosum diarrhea LN enlargement sigmoido-vesical fistula | Infliximab seems to increase the risk of exacerbation of WD | |
| [ | Razonable R.R. et al. | Transpl. Infect. Dis. | 2008 | 1 | Kidney Transplant and migratory poly arthritis, weight loss, GIT-symptoms for years | Azathioprim/Prednison | Chorioretinitis and Vitreitis | Tropheryma whipplei DNA in vitrous fluid and peripheral blood |
| [ | Kremer AE. et al. | Z. Gastroenterolog. | 2008 | 1 | SNRA/4 yrs | Adalimumab/Leflunomid | Septic fever severe arthralgia weight loss | Immunmodulatory therapies, TNF blockers and Corticosteroids may lead to exercerbation of subacute, undiagnosed Whipples Disease |
| [ | Spoerl D. et al. | Orphanet. J. Rare Dis. | 2009 | 1 | Multisegment spondylitis | TNF-a | Worsening back pain | TNF-a treatment worsened spondylodiscitis, leading to diagnosis of T. Whipplei from rebiopsy of vertebral specimen |
| [ | Lagier J-C et al. | Medicine | 2010 | 113 | 5 of 16 patients with endocarditis as initial symptoms had immunosuppressive treatment | Corticosteroids 50 (43 %) TNF-a antagonists 16 (14 %) Others 16 (14 %) Previous immuno suppressive Treatment 56 (50 %) | 32 patients (28 %) experienced aggravation of various symptoms after immunosuppressive therapy | Patients with inflammatory rheumatoid disease who experience severe general involvment should be screened for T. Whippelii or the therapy is inneffective against polyarthritis |
| [ | Hoppe E. et al. | Joint bone Spine | 2010 | 5 | RA(2), AS(2), SA(1) | TNF a antagonists | Failure to control the disease and other symptoms | Biological therapy probably worsened pre existing whipples disease |
| [ | Vancsa A et al. | Joint Bone Spine | 2010 | 1 | Seronegative Oligoarthritis | Eternecept | Endocarditis | DMARDs resistant arthritis should prompt thourough search T.whippelii prior to initiation of TNF-a antagonists |
| [ | Hmamouci I et al. | J. Rheumatol. | 2010 | 1 | Ankylosing spondylitis | Eternecept | Scurvy | Eternecept probably modified the cytokine environment and thus favoured exercerbation of whipples disease |
| [ | Daien C.I. et al. | Rheumatology | 2010 | 1 | B-27- negative Ankylosing spondylitis | Eternecept | Endocarditis | Report of the first case of t. Whippeliis endocarditis, potentially induced by TNF-a antagonist therapy |
| [ | Gaddy J.R. | Rheumatology | 2012 | 1 | Back pain; Arthritis | Various TNF a Inhibitors | Fever, migratory arthritis | Clinical deterioration despite TNF a antagonists lead to thorough search and T. Whipelli was found |
| [ | Sparsa L et al. | La Revue de medecine interne | 2013 | 2 | Spondyloarthritis (both patients) | Eternecept/adalimumab (Both patients) | peristent elevated acute phase reactants | Whipples disease should be suspected in patients with treated with TNF a antagonists who do not improve during inflammatory rheumatism |
| [ | Marth T. | World J. Cardiol. | 2014 | 41vs 61vs1059 | Arthritis | TNF-a/41 patients | 12.2 % vs 1.6 % vs 0.16 % endocarditis rates | TNF-a triggered severe whipples disease complications particularly endocarditis |
| [ | Marth T. | Aliment. Pharmacol. Ther. | 2015 | 41 | Arthritis, weight-loss, Diarrhea | Various TNF-a Inhibitors | Fever, septic temperatures (n, 16), Tropheryma whipplei septicemia (n, 6), Endocarditis (n, 5) etc. | In case of doubt, Whipples disease should be excluded before therapy with TNF-a |